India, Feb. 23 -- Morepen Laboratories has secured a multi-year Contract Development and Manufacturing Organization (CDMO) mandate valued at approximately Rs 825 crore ($91 million) from a leading global pharma major.

Supplies under the mandate are expected to commence within the next 4-5 months, with execution scheduled through Q1 of the following financial year, subject to customary operational and regulatory processes.

This engagement marks one of the most significant single CDMO mandates in the company's history, as it scales its global manufacturing footprint.

Built on over four decades of API manufacturing expertise and regulatory credibility, Morepen's CDMO platform enables deeper collaboration with global pharmaceutical innovat...